Daniel Himmelstein (@dhimmel)
GDG Cloud DevFest Philly
Indy Hall · 399 Market St #360
September 28, 2019 1:00 PM
slides.com/dhimmel/devfest
slides released under CC BY 4.0
http://www.greenelab.com/
Special thanks to
Short Abstract:
How can we encode all biomedical knowledge into a single resource optimized for machine learning? We explore using hetnets (networks with multiple node and relationship types) and graph databases to integrate diverse information. By combining data from 29 public resources, we created Hetionet, a network with 11 node and 24 relationship types (available at https://neo4j.het.io). Next, we learned which types of paths occur more frequently when a drug treats a disease, allowing us to make over 200,000 predictions of treatment efficacy. Now we are creating a search engine at https://search.het.io/ to allow any researcher to quickly find how any two nodes in the hetnet are meaningfully connected. These studies were made possible by adopting a set of radically open practices, where all research was shared and discussed publicly from its inception. This includes our new Manubot software for open scholarly writing on GitHub.
Short Bio:
Daniel Himmelstein is a postdoctoral fellow in the Greene Lab at the University of Pennsylvania. Previously, he received his PhD from the University of California San Francisco. His research focuses on integrating biomedical knowledge using networks. Daniel is also a frequent contributor to open source/data ecosystems, and explores how computational research can become more open and reproducible.
too simple
single node type
single relationship type
networks with multiple node or relationship types
multilayer network, multiplex network, multivariate network, multinetwork, multirelational network, multirelational data, multilayered network, multidimensional network, multislice network, multiplex of interdependent networks, hypernetwork, overlay network, composite network, multilevel network, multiweighted graph, heterogeneous network, multitype network, interconnected networks, interdependent networks, partially interdependent networks, network of networks, coupled networks, interconnecting networks, interacting networks, heterogenous information network
A 2012 Study identified 26 different names for this type of network:
hetnet
Visualizing Hetionet v1.0
MATCH path =
// Specify the type of path to match
(n0:Disease)-[e1:ASSOCIATES_DaG]-(n1:Gene)-[:INTERACTS_GiG]-
(n2:Gene)-[:PARTICIPATES_GpBP]-(n3:BiologicalProcess)
WHERE
// Specify the source and target nodes
n0.name = 'multiple sclerosis' AND
n3.name = 'retina layer formation'
// Require GWAS support for the
// Disease-associates-Gene relationship
AND 'GWAS Catalog' in e1.sources
// Require the interacting gene to be
// upregulated in a relevant tissue
AND exists(
(n0)-[:LOCALIZES_DlA]-(:Anatomy)-[:UPREGULATES_AuG]-(n2))
RETURN path
More queries at thinklab.com/d/220
Hetionet v1.0 contains:
1,538 connected compounds
136 connected diseases
209,168 compound–disease pairs
755 treatments
Systematic drug repurposing:
Compare the therapeutic utility of data types
Identify the mechanisms of drug efficacy
Predict the probability of treatment for all 209,168 compound–disease pairs (het.io/repurpose)
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Daniel S Himmelstein, Antoine Lizee, Christine Hessler, Leo Brueggeman, Sabrina L Chen, Dexter Hadley, Ari Green, Pouya Khankhanian, Sergio E Baranzini
eLife (2017) https://doi.org/cdfk
observations =
compound–disease pairs
features = types of paths
treatments
disease modifying treatments
+755, −208,413
AUROC = 97.4%
treatments with clinical trials
+5,594, −202,186
AUROC = 70.0%
Compound–causes–Side Effect–causes–Compound–treats–Disease
Compound–binds–Gene–associates–Disease
Compound–binds–Gene–participates–Pathway–participates–Disease
Browse all predictions at het.io/repurpose. Discuss at thinklab.com/d/224
Discuss at thinklab.com/d/224#5
Discuss at thinklab.com/d/230#14
https://het.io/software/
https://het.io/search/
https://het.io/search/?source=17054&target=6602
we report that in human cancer cells, metformin inhibits mitochondrial complex I (NADH dehydrogenase) activity and cellular respiration.
— Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
Wheaton et al (2014) eLife https://doi.org/gfpb2x
Metformin is the most widely used antidiabetic drug in the world, and there is increasing evidence of a potential efficacy of this agent as an anticancer drug. First, epidemiological studies show a decrease in cancer incidence in metformin-treated patients.
— Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?
Sahra et al (2010) Mol Cancer Ther https://doi.org/bgr5vv
Beyond the PDF First Day Notes
By De Jongens van de Tekeningen
Licensed under CC BY 3.0
Modified to invert colors
The Deep Review
most viewed bioRxiv preprint of 2017
This is a sentence with 5 citations [ @doi:10.1038/nbt.3780; @pmid:29424689; @pmcid:PMC5938574; @arxiv:1407.3561; @url:https://greenelab.github.io/meta-review/ ].
This is a sentence with 5 citations [1,2,3,4,5].
input
output
manubot process
Grant G-2018-11163 to DSH
https://manubot.org/catalog/
convert rms-fsf-slide-propreitary.png -channel RGB -negate -transparent black rms-fsf-slide-propreitary-negated.png
FreeSoftware TEDx slides. (2014) Reused under CC BY 3.0
FreeSoftware TEDx slides. (2014) Reused under CC BY 3.0
convert rms-fsf-slide.png -channel RGB -negate -transparent black rms-fsf-slide-negated.png
Recommendations:
@dhimmel
0000-0002-3012-7446
Slides
https://slides.com/dhimmel/devfest